Showing 11-20 of 34 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Closing the T1D diagnosis gap in Ethiopia, Ghana and Nigeria | Clinton Health Access Initiative (CHAI) | Margaret Prust | Mission | 01-September-2023 to 31-August-2026 | $1.702.076,57 |
| Subcutaneous In Vivo Engraftment and Vascularization of 3D Bioprinted Pancreatic-Like Tissue | FluidForm Bio | Adam Feinberg | Cures | 23-December-2025 to 12-June-2026 | $228.696,00 |
| GNTI-122 for the treatment of recently diagnosed type 1 diabetes | GentiBio | Mark Bach | Cures | 01-February-2025 to 13-February-2028 | $4.000.000,00 |
| Advanced Oxygen Generator for Oxygenated Cell Capsules | Giner, Inc. | Linda Tempelman | Cures | 01-June-2021 to 30-September-2026 | $448.173,29 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8.913.450,00 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212.708,89 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 30-June-2027 | $1.341.376,33 |
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $216.326,98 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1.349.997,00 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 15-May-2026 to 31-May-2027 | $200.000,00 |